Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.65 |
| ▸ | MAP2K2 | P36507 | 12/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391687 | 0.92 | MAP2K1 (0.53) | MAP2K1MAP2K2POLBP2RX7NPC1 | |
| SCHEMBL388534 | 0.85 | MAP2K1 (0.57) | MAP2K1MAP2K2POLBADRA1DP2RX7 | |
| SCHEMBL392975 | 0.85 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL392788 | 0.84 | MAP2K1 (0.66) | MAP2K1MAP2K2POLBADRA1DP2RX7 | |
| SCHEMBL391989 | 0.83 | MAP2K1 (0.72) | MAP2K1MAP2K2POLB | |
| SCHEMBL392685 | 0.80 | MAP2K1 (0.57) | MAP2K1MAP2K2POLBNPC1 | |
| SCHEMBL392481 | 0.79 | MAP2K1 (0.67) | MAP2K1MAP2K2POLBNPC1 | |
| SCHEMBL392242 | 0.79 | MAP2K1 (1.00) | MAP2K1MAP2K2 | |
| SCHEMBL12954658 | 0.79 | MAP2K2 (0.48) | MAP2K1MAP2K2P2RX7 | |
| SCHEMBL14549267 | 0.76 | MAP2K1 (0.48) | MAP2K1MAP2K2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293544-A1 | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | MERCK SERONO SA (CH) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293544-A1 | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | BRAF, MAP3K19, MAPK1 | MAP2K1 65/4885MAP2K2 62/4885POLB 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.